| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 21 | 2025 | 1031 | 2.470 |
Why?
|
| Liver Failure, Acute | 9 | 2024 | 89 | 1.960 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2025 | 26 | 1.890 |
Why?
|
| Hypertension, Portal | 5 | 2017 | 78 | 1.510 |
Why?
|
| Chemical and Drug Induced Liver Injury | 5 | 2024 | 106 | 1.410 |
Why?
|
| Hepatic Encephalopathy | 14 | 2015 | 75 | 1.350 |
Why?
|
| Acetaminophen | 6 | 2024 | 91 | 1.300 |
Why?
|
| Extracorporeal Circulation | 9 | 2019 | 56 | 1.160 |
Why?
|
| Hypertension, Pulmonary | 5 | 2017 | 438 | 1.150 |
Why?
|
| Liver Failure | 6 | 2017 | 89 | 1.030 |
Why?
|
| Liver, Artificial | 4 | 2014 | 9 | 1.020 |
Why?
|
| Artificial Organs | 9 | 1996 | 14 | 1.010 |
Why?
|
| Drug Overdose | 5 | 2024 | 66 | 0.990 |
Why?
|
| Endpoint Determination | 1 | 2025 | 56 | 0.950 |
Why?
|
| Clinical Trials as Topic | 3 | 2025 | 1090 | 0.870 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2024 | 57 | 0.810 |
Why?
|
| Liver | 16 | 2024 | 1742 | 0.790 |
Why?
|
| Hepacivirus | 3 | 2018 | 243 | 0.770 |
Why?
|
| Hepatocytes | 4 | 2012 | 208 | 0.650 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2019 | 2 | 0.630 |
Why?
|
| Hepatitis C | 3 | 2018 | 366 | 0.610 |
Why?
|
| Analgesics | 1 | 2019 | 126 | 0.610 |
Why?
|
| Alcoholism | 2 | 2024 | 231 | 0.570 |
Why?
|
| Ammonia | 2 | 2015 | 75 | 0.500 |
Why?
|
| Rifamycins | 1 | 2015 | 21 | 0.480 |
Why?
|
| Lactulose | 1 | 2015 | 39 | 0.480 |
Why?
|
| Digestive System Neoplasms | 1 | 2015 | 14 | 0.480 |
Why?
|
| Gastrointestinal Agents | 1 | 2015 | 60 | 0.470 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2015 | 59 | 0.450 |
Why?
|
| Models, Statistical | 2 | 2017 | 472 | 0.440 |
Why?
|
| Hepatitis C, Chronic | 3 | 2016 | 325 | 0.440 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 181 | 0.430 |
Why?
|
| Disease Eradication | 1 | 2014 | 32 | 0.430 |
Why?
|
| Humans | 59 | 2025 | 124700 | 0.420 |
Why?
|
| Antiviral Agents | 3 | 2016 | 750 | 0.400 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2011 | 8 | 0.370 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 360 | 0.370 |
Why?
|
| Citrullinemia | 1 | 2010 | 15 | 0.350 |
Why?
|
| Models, Biological | 2 | 2013 | 1460 | 0.350 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2023 | 46 | 0.340 |
Why?
|
| 5-Aminolevulinate Synthetase | 1 | 2008 | 2 | 0.310 |
Why?
|
| Iron Overload | 1 | 2008 | 16 | 0.310 |
Why?
|
| Anemia, Sideroblastic | 1 | 2008 | 17 | 0.310 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2008 | 64 | 0.300 |
Why?
|
| Biomedical Research | 1 | 2014 | 519 | 0.300 |
Why?
|
| Cation Transport Proteins | 1 | 2008 | 92 | 0.290 |
Why?
|
| Antihypertensive Agents | 2 | 2011 | 412 | 0.280 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2007 | 7 | 0.280 |
Why?
|
| Liver Cirrhosis | 2 | 2011 | 832 | 0.270 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 204 | 0.270 |
Why?
|
| Ascites | 1 | 2007 | 88 | 0.270 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2004 | 154 | 0.260 |
Why?
|
| Hepatitis E | 1 | 2006 | 4 | 0.260 |
Why?
|
| Tissue Donors | 3 | 2018 | 494 | 0.250 |
Why?
|
| Epoprostenol | 1 | 2006 | 69 | 0.250 |
Why?
|
| Sitosterols | 1 | 2025 | 9 | 0.240 |
Why?
|
| Liver Diseases | 3 | 2018 | 365 | 0.240 |
Why?
|
| Travel | 1 | 2006 | 113 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 290 | 0.230 |
Why?
|
| Abdominal Pain | 1 | 2007 | 308 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 275 | 0.230 |
Why?
|
| Research Design | 2 | 2025 | 692 | 0.220 |
Why?
|
| Mutation, Missense | 1 | 2008 | 874 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2025 | 12363 | 0.210 |
Why?
|
| Drug Design | 1 | 2004 | 151 | 0.210 |
Why?
|
| Adult | 17 | 2025 | 29555 | 0.200 |
Why?
|
| Pulmonary Artery | 3 | 2017 | 442 | 0.190 |
Why?
|
| Administration, Oral | 2 | 2014 | 683 | 0.190 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 343 | 0.190 |
Why?
|
| Middle Aged | 16 | 2025 | 26884 | 0.180 |
Why?
|
| Patient Selection | 1 | 2025 | 697 | 0.180 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2000 | 46 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2023 | 296 | 0.170 |
Why?
|
| Male | 24 | 2025 | 61314 | 0.170 |
Why?
|
| Professional Practice Location | 1 | 2019 | 7 | 0.160 |
Why?
|
| Gastroenterologists | 1 | 2019 | 11 | 0.160 |
Why?
|
| Alkaline Phosphatase | 3 | 1989 | 97 | 0.160 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 37 | 0.160 |
Why?
|
| Renal Dialysis | 3 | 1996 | 854 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2019 | 173 | 0.150 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2018 | 43 | 0.150 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2024 | 72 | 0.150 |
Why?
|
| Donor Selection | 1 | 2018 | 55 | 0.150 |
Why?
|
| Alanine Transaminase | 3 | 2013 | 157 | 0.140 |
Why?
|
| Hemodynamics | 2 | 2012 | 852 | 0.140 |
Why?
|
| Arterial Pressure | 2 | 2017 | 112 | 0.140 |
Why?
|
| Tissue and Organ Procurement | 2 | 2017 | 224 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 2161 | 0.140 |
Why?
|
| Narcotics | 1 | 2017 | 63 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2019 | 217 | 0.140 |
Why?
|
| Female | 20 | 2025 | 66570 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2016 | 14 | 0.130 |
Why?
|
| Immunoassay | 1 | 2016 | 130 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 505 | 0.130 |
Why?
|
| Headache | 1 | 2016 | 107 | 0.130 |
Why?
|
| Graft Survival | 2 | 2019 | 536 | 0.130 |
Why?
|
| Aspartate Aminotransferases | 2 | 2013 | 82 | 0.120 |
Why?
|
| Time Factors | 4 | 2019 | 6323 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2017 | 227 | 0.120 |
Why?
|
| Liver Regeneration | 4 | 1996 | 36 | 0.120 |
Why?
|
| Ornithine | 1 | 2015 | 31 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2019 | 590 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 2015 | 15 | 0.120 |
Why?
|
| Dogs | 5 | 1994 | 774 | 0.120 |
Why?
|
| Glycerol | 1 | 2015 | 97 | 0.120 |
Why?
|
| Dipeptides | 1 | 2015 | 56 | 0.120 |
Why?
|
| United States | 7 | 2023 | 10866 | 0.120 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2015 | 77 | 0.120 |
Why?
|
| Phenylbutyrates | 1 | 2015 | 58 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 2900 | 0.120 |
Why?
|
| Arteriovenous Fistula | 1 | 2015 | 57 | 0.120 |
Why?
|
| Blood Pressure | 3 | 2012 | 1369 | 0.120 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 95 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2024 | 16262 | 0.110 |
Why?
|
| Liver Function Tests | 2 | 2010 | 101 | 0.110 |
Why?
|
| Hepatitis | 1 | 1994 | 57 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 105 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 107 | 0.110 |
Why?
|
| Prognosis | 5 | 2023 | 4620 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 143 | 0.110 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 180 | 0.110 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2013 | 3 | 0.110 |
Why?
|
| Assisted Circulation | 1 | 1993 | 36 | 0.110 |
Why?
|
| Animals | 14 | 2019 | 34234 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 772 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 726 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1260 | 0.100 |
Why?
|
| Schistosomiasis mansoni | 1 | 2012 | 24 | 0.100 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 41 | 0.100 |
Why?
|
| Probiotics | 1 | 2015 | 215 | 0.100 |
Why?
|
| Malnutrition | 1 | 2015 | 205 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 1305 | 0.100 |
Why?
|
| Blood Proteins | 1 | 1992 | 124 | 0.100 |
Why?
|
| Hepatectomy | 1 | 1992 | 110 | 0.090 |
Why?
|
| Risk Factors | 5 | 2019 | 10249 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 306 | 0.090 |
Why?
|
| Argininosuccinate Synthase | 1 | 2010 | 21 | 0.090 |
Why?
|
| Creatinine | 1 | 2012 | 391 | 0.090 |
Why?
|
| Fibrosis | 1 | 2012 | 435 | 0.090 |
Why?
|
| Aged | 9 | 2025 | 19830 | 0.090 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2010 | 33 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1872 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 1159 | 0.090 |
Why?
|
| Gastroenterology | 1 | 2012 | 196 | 0.080 |
Why?
|
| Cell Line | 4 | 2000 | 2757 | 0.080 |
Why?
|
| Diet, Protein-Restricted | 1 | 2010 | 81 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 1775 | 0.080 |
Why?
|
| Citrulline | 1 | 2010 | 108 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 575 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3714 | 0.080 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 119 | 0.070 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 794 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2010 | 867 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 398 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2018 | 6132 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2043 | 0.070 |
Why?
|
| Veterans | 1 | 2018 | 1749 | 0.070 |
Why?
|
| Computer Simulation | 2 | 2013 | 649 | 0.070 |
Why?
|
| Recurrence | 1 | 2010 | 1415 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 332 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 920 | 0.060 |
Why?
|
| Jaundice | 1 | 2006 | 27 | 0.060 |
Why?
|
| Cause of Death | 2 | 2019 | 474 | 0.060 |
Why?
|
| India | 1 | 2006 | 213 | 0.060 |
Why?
|
| Isoenzymes | 1 | 1986 | 228 | 0.060 |
Why?
|
| Intestines | 1 | 1989 | 576 | 0.060 |
Why?
|
| Registries | 2 | 2024 | 1428 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 554 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2018 | 538 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 1290 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2019 | 3444 | 0.060 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2004 | 15 | 0.060 |
Why?
|
| Toxicology | 1 | 2004 | 9 | 0.060 |
Why?
|
| Young Adult | 4 | 2019 | 9022 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2004 | 62 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2006 | 355 | 0.060 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 495 | 0.050 |
Why?
|
| Cysteine | 1 | 2024 | 137 | 0.050 |
Why?
|
| Biological Assay | 1 | 2004 | 104 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2008 | 638 | 0.050 |
Why?
|
| Intestine, Small | 1 | 1986 | 309 | 0.050 |
Why?
|
| Caspases | 1 | 2004 | 162 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2004 | 295 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2006 | 759 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 282 | 0.050 |
Why?
|
| alpha-Fetoproteins | 2 | 1994 | 132 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2009 | 3055 | 0.050 |
Why?
|
| North America | 1 | 2023 | 239 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2018 | 1176 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 1986 | 663 | 0.050 |
Why?
|
| Serum Albumin | 2 | 1994 | 110 | 0.050 |
Why?
|
| Coma | 1 | 2023 | 56 | 0.050 |
Why?
|
| RNA | 1 | 1986 | 570 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 122 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2025 | 1637 | 0.050 |
Why?
|
| Equipment Design | 2 | 1994 | 598 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2002 | 36 | 0.050 |
Why?
|
| Biomarkers | 1 | 2010 | 3083 | 0.050 |
Why?
|
| Ischemia | 1 | 2024 | 361 | 0.050 |
Why?
|
| Triazoles | 1 | 2002 | 138 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 634 | 0.040 |
Why?
|
| Cytochrome P-450 CYP1A2 Inhibitors | 1 | 2000 | 3 | 0.040 |
Why?
|
| Theophylline | 1 | 2000 | 29 | 0.040 |
Why?
|
| Methylcholanthrene | 1 | 2000 | 19 | 0.040 |
Why?
|
| Oxazines | 1 | 2000 | 25 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2000 | 104 | 0.040 |
Why?
|
| Fluorescence | 1 | 2000 | 96 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1994 | 1063 | 0.040 |
Why?
|
| Vascular Resistance | 2 | 2017 | 189 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 28 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5154 | 0.040 |
Why?
|
| Hepatitis Viruses | 1 | 2018 | 3 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 190 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2002 | 454 | 0.040 |
Why?
|
| Pregnancy | 1 | 2010 | 7171 | 0.040 |
Why?
|
| Allografts | 1 | 2018 | 190 | 0.040 |
Why?
|
| Portal Pressure | 1 | 2017 | 5 | 0.040 |
Why?
|
| Metagenomics | 1 | 2018 | 102 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 579 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2004 | 2304 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 19216 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2018 | 480 | 0.030 |
Why?
|
| Mutation | 1 | 2010 | 5845 | 0.030 |
Why?
|
| Pulmonary Circulation | 1 | 2017 | 121 | 0.030 |
Why?
|
| Jejunum | 2 | 1988 | 127 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 1996 | 69 | 0.030 |
Why?
|
| Oxygen Consumption | 2 | 1996 | 306 | 0.030 |
Why?
|
| Age Factors | 2 | 2019 | 2807 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 41 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 588 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1287 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 538 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 1996 | 141 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 672 | 0.030 |
Why?
|
| Sorption Detoxification | 1 | 1994 | 2 | 0.030 |
Why?
|
| Giant Cells | 1 | 1994 | 34 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1994 | 89 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1052 | 0.030 |
Why?
|
| Survival Rate | 2 | 1996 | 2055 | 0.030 |
Why?
|
| Galactose | 1 | 1994 | 54 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 383 | 0.030 |
Why?
|
| Rats | 4 | 1989 | 3728 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 490 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1437 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1357 | 0.030 |
Why?
|
| Pilot Projects | 2 | 1996 | 1396 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 1994 | 150 | 0.030 |
Why?
|
| Life Support Systems | 1 | 1993 | 5 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 882 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1993 | 394 | 0.030 |
Why?
|
| Transferrin | 1 | 1992 | 50 | 0.020 |
Why?
|
| Rats, Inbred Strains | 3 | 1988 | 233 | 0.020 |
Why?
|
| Methionine Sulfoximine | 1 | 1992 | 1 | 0.020 |
Why?
|
| Methemoglobinemia | 1 | 1992 | 8 | 0.020 |
Why?
|
| Vacuoles | 1 | 1992 | 24 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1992 | 83 | 0.020 |
Why?
|
| Buthionine Sulfoximine | 1 | 1992 | 28 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 1992 | 47 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2885 | 0.020 |
Why?
|
| Algorithms | 1 | 2018 | 1625 | 0.020 |
Why?
|
| Carbolines | 1 | 1991 | 8 | 0.020 |
Why?
|
| Critical Care | 1 | 1996 | 655 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3415 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 1991 | 74 | 0.020 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1989 | 1 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 1989 | 24 | 0.020 |
Why?
|
| Phospholipase D | 1 | 1989 | 7 | 0.020 |
Why?
|
| Monensin | 1 | 1989 | 10 | 0.020 |
Why?
|
| Butyric Acid | 1 | 1989 | 7 | 0.020 |
Why?
|
| Microvilli | 1 | 1989 | 71 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1989 | 65 | 0.020 |
Why?
|
| Butyrates | 1 | 1989 | 35 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 1992 | 681 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1989 | 94 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 314 | 0.020 |
Why?
|
| Ileum | 1 | 1989 | 132 | 0.020 |
Why?
|
| Duodenum | 1 | 1989 | 99 | 0.020 |
Why?
|
| Apoproteins | 1 | 1988 | 18 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 1988 | 46 | 0.020 |
Why?
|
| Biopsy | 1 | 1992 | 1234 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1992 | 1136 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6584 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 248 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1988 | 297 | 0.020 |
Why?
|
| Common Bile Duct | 1 | 1986 | 14 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1986 | 15 | 0.020 |
Why?
|
| Contraindications | 1 | 2006 | 78 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1986 | 106 | 0.020 |
Why?
|
| Microsomes | 1 | 1986 | 56 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1986 | 63 | 0.020 |
Why?
|
| Ribavirin | 1 | 2006 | 79 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 227 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1991 | 688 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2006 | 229 | 0.010 |
Why?
|
| Child | 2 | 1994 | 24170 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 1399 | 0.010 |
Why?
|
| Peptides | 1 | 1986 | 810 | 0.010 |
Why?
|
| Priapism | 1 | 2002 | 10 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1989 | 1022 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1989 | 1896 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1986 | 2717 | 0.010 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2002 | 41 | 0.010 |
Why?
|
| Piperazines | 1 | 2002 | 239 | 0.010 |
Why?
|
| Suicide | 1 | 2002 | 175 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1695 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 990 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 1191 | 0.010 |
Why?
|
| Factor V | 1 | 1996 | 18 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 870 | 0.010 |
Why?
|
| Platelet Count | 1 | 1996 | 136 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1996 | 171 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1996 | 155 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1988 | 2821 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 2248 | 0.010 |
Why?
|
| Apolipoproteins A | 1 | 1988 | 47 | 0.000 |
Why?
|
| Apolipoprotein A-I | 1 | 1988 | 81 | 0.000 |
Why?
|
| Organ Culture Techniques | 1 | 1988 | 156 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1991 | 816 | 0.000 |
Why?
|
| Apolipoproteins E | 1 | 1988 | 192 | 0.000 |
Why?
|
| Immune Sera | 1 | 1986 | 95 | 0.000 |
Why?
|
| Ligation | 1 | 1986 | 135 | 0.000 |
Why?
|
| Triglycerides | 1 | 1988 | 577 | 0.000 |
Why?
|
| Cholesterol | 1 | 1988 | 539 | 0.000 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1986 | 358 | 0.000 |
Why?
|
| Placenta | 1 | 1986 | 508 | 0.000 |
Why?
|